Inhaled sodium cromoglycate in angiotensin-converting enzyme inhibitor cough
| Autor: | M.K Benson, M.R Hargreaves |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
medicine.medical_treatment Angiotensin-Converting Enzyme Inhibitors Placebo chemistry.chemical_compound Double-Blind Method Administration Inhalation Cromolyn Sodium medicine Humans Aged Chemotherapy Cross-Over Studies biology Inhalation business.industry Angiotensin-converting enzyme General Medicine Middle Aged Crossover study respiratory tract diseases chemistry Cough Capsaicin Anesthesia Toxicity biology.protein Female business |
| Zdroj: | Lancet (London, England). 345(8941) |
| ISSN: | 0140-6736 |
| Popis: | Cough is a frequent side-effect of angiotensin-converting enzyme (ACE) inhibitors. We examined the effects of inhaled sodium cromoglycate in 10 patients with ACE-inhibitor cough in a double-blind crossover study. After a 2-week run-in, patients were randomised to either 2 weeks' inhaled sodium cromoglycate or placebo followed by a further 2 weeks on the other treatment. Patients kept a cough diary during each study period. Cough severity was recorded on a scale from 0 to 12. At the end of each study period the cough threshold to inhaled capsaicin was measured. 9 patients reported a reduction in cough after sodium cromoglycate. Median (range) daily cough scores during run-in and placebo periods were 3.6 (1.9-6.4) and 4.1 (0.6-8.1), respectively (p > 0.05). Median daily cough score after sodium cromoglycate was 1.8 (0.4-3; p < 0.01). There was a significant relation between initial cough severity and benefit from sodium cromoglycate; and cough-reflex sensitivity to inhaled capsaicin was significantly reduced. Inhaled sodium cromoglycate is an effective treatment for ACE-inhibitor cough. Its effect may be due to suppression of afferent vagal activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |